According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer’s drug, Aduhelm, that was submitted to medical journal JAMA.

Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (

The U.S. Food and Drug Administration last month approved Aduhelm despite strong objection from its own expert advisory panel, citing convincing evidence that Aduhelm can clear amyloid brain plaques and benefit Alzheimer’s patients.

Many experts have also raised questions about whether there is evidence that the drug slows cognitive decline.